All sponsors

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS11
PHASE 3 / 2-34
RECRUITING3
READOUTS ≤12 MONTHS6
READOUT SLIPPED >6 MO33%

Delay Index: of 6 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Jiangsu Alphamab Biopharmaceuticals Co., Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
JSKN003
NCT06079983
P3RecruitingBreast Cancer4002026-04-01 (+12 mo)
JSKN003
NCT05744427
P1/2Active, not recruitingAdvanced Solid Tumor7252026-07-30 (+19 mo)
JSKN003
NCT06751485
P3Not yet recruitingOvarian Cancer; Primary Peritoneal4302026-12-30
JSKN033
NCT06770881
P1/2Not yet recruitingAdvanced Malignant Tumors4302026-12-31
JSKN016
NCT06942234
P1/2RecruitingInoperable Locally Advanced HER2-Negative Breast Cancer; Metastatic HER2-Negative Breast Cancer1802027-06-30
JSKN016
NCT06775483
P2Not yet recruitingAdvanced Non-small Cell Lung Cancer2202027-06-30
JSKN033 Injection
NCT07283198
P2Not yet recruitingNon Small Cell Lung Cancer (NSCLC)1602027-08-30
JSKN033
NCT07497074
P2Not yet recruitingCervical Cancer782027-10
JSKN016 Q2W
NCT07336771
P1/2Not yet recruitingMetastatic Breast Cancer; Locally Advanced Breast Cancer (LABC)602027-12
JSKN033
NCT07797153
P3Not yet recruitingRecurrent or Metastatic Cervical Cancer3682028-12
JSKN016 Injection
NCT07533123
P3RecruitingTriple Negative Breast Cancer3642029-03-17